**Acknowledgements**

The work on TLR-3 was supported by a grant to author from National Institutes of Health, National Institutes on Aging (1R21AG044068). The human brain sections were provided to author from the Banner Sun Health Research Institute Brain and Body Donation Program. The operation of the Banner Sun Health Research Institute Brain and Body Donation Program has been supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (Contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson's Research (The Prescott Family Initiative).

[7] Rojas-Gutierrez E, Munoz-Arenas G, Trevino S, Espinosa B, Chavez R, Rojas K, et al. Alzheimer's disease and metabolic syndrome: A link from oxidative stress and inflam-

Defining Microglial Phenotypes in Alzheimer's Disease http://dx.doi.org/10.5772/intechopen.75511 53

[8] Ardura-Fabregat A, Boddeke EWGM, Boza-Serrano A, Brioschi S, Castro-Gomez S, Ceyzeriat K, et al. Targeting neuroinflammation to treat Alzheimer's disease. CNS

[9] McGeer PL, Kawamata T, Walker DG, Akiyama H, Tooyama I, McGeer EG. Microglia in degenerative neurological disease. Glia. 1993;**7**:84-92. DOI: 10.1002/glia.440070114 [10] Minett T, Classey J, Matthews FE, Fahrenhold M, Taga M, Brayne C, et al. Microglial immunophenotype in dementia with Alzheimer's pathology. Journal of Neuroinflammation.

[11] Akiyama H, McGeer PL. Brain microglia constitutively express beta-2 integrins. Journal

[12] Roe MT, Dawson DV, Hulette CM, Einstein G, Crain BJ. Microglia are not exclusively associated with plaque-rich regions of the dentate gyrus in Alzheimer's disease. Journal

[13] Kaneko Y, Kitamoto T, Tateishi J, Yamaguchi K. Ferritin immunohistochemistry as a

[14] Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S, et al. Inflammatory components in human Alzheimer's disease and after active amyloid-beta42 immuniza-

[15] Wojtera M, Sobow T, Kloszewska I, Liberski PP, Brown DR, Sikorska B. Expression of immunohistochemical markers on microglia in Creutzfeldt-Jakob disease and Alzheimer's disease: Morphometric study and review of the literature. Folia Neuropathologica.

[16] Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and

[17] Lyketsos CG, Breitner JCS, Green RC, Martin BK, Meinert C, Piantadosi S, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.

[18] Meinert CL, Breitner JCS. Chronic disease long-term drug prevention trials: Lessons from the Alzheimer's disease anti-inflammatory prevention trial (ADAPT). Alzheimer's

[19] Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D.Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. Journal of Neuroimmunology. 1989;**24**:173-182

[20] Klegeris A, Walker DG, McGeer PL. Activation of macrophages by Alzheimer beta amyloid peptide. Biochemical and Biophysical Research Communications. 1994;**199**:984-991.

Neurology. 2007;**68**:1800-1808. DOI: 10.1212/01.wnl.0000260269.93245.d2

& Dementia. 2008;**4**(Suppl. 1):S7-S14. DOI: 10.1016/j.jalz.2007.10.007

of Neuropathology and Experimental Neurology. 1996;**55**:366-371

marker for microglia. Acta Neuropathologica. 1989;**79**:129-136

tion. Brain. 2013;**136**:2677-2696. DOI: 10.1093/brain/awt210

Alzheimer's disease. Neurobiology of Aging. 2000;**21**:383-421

mation to neurodegeneration. Synapse. 2017. DOI: 10.1002/syn.21990

Drugs. 2017;**31**:1057-1082. DOI: 10.1007/s40263-017-0483-3

2016;**13**:135. DOI: 10.1186/s12974-016-0601-z

of Neuroimmunology. 1990;**30**:81-93

2012;**50**:74-84

DOI: 10.1006/bbrc.1994.1326
